NVO · PEAD ↑ 91

Novo Nordisk reported Q2 2026 EPS of $4.75 on 2026-08-05, beating the $0.81 consensus by $3.94 (+486.4%).

Print-day reaction was a muted +0.6% versus the prior close, a surprisingly modest move given the magnitude of the consensus beat. The overnight gap to the T+1 open added +2.4%, signalling that the market's reassessment continued well after the close rather than fading. Over the subsequent three trading days the price drifted +3.8% from the T+1 close to the T+3 close, confirming a clean continuation of the upward bias. Cumulative abnormal return of +7.6% versus SPY.US firmly puts this in PEAD long territory; the documented drift pattern holds through 2026-11-02.